## Giovanni Frisullo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3163773/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Modulation of LTP at rat hippocampal CA3-CA1 synapses by direct current stimulation. Journal of Neurophysiology, 2012, 107, 1868-1880.	1.8	183
2	Focal status epilepticus as unique clinical feature of COVID-19: A case report. Seizure: the Journal of the British Epilepsy Association, 2020, 78, 109-112.	2.0	152
3	Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial. Lancet Neurology, The, 2018, 17, 1053-1060.	10.2	146
4	pSTAT1, pSTAT3, and T-bet expression in peripheral blood mononuclear cells from relapsing-remitting multiple sclerosis patients correlates with disease activity. Journal of Neuroscience Research, 2006, 84, 1027-1036.	2.9	129
5	CD8+ T Cells in Facioscapulohumeral Muscular Dystrophy Patients with Inflammatory Features at Muscle MRI. Journal of Clinical Immunology, 2011, 31, 155-166.	3.8	113
6	Global impact of COVID-19 on stroke care. International Journal of Stroke, 2021, 16, 573-584.	5.9	104
7	Leptin as a marker of multiple sclerosis activity in patients treated with interferon-beta. Journal of Neuroimmunology, 2003, 139, 150-154.	2.3	94
8	Correlations between peripheral blood mononuclear cell production of BDNF, TNFâ€alpha, ILâ€6, ILâ€10 and cognitive performances in multiple sclerosis patients. Journal of Neuroscience Research, 2010, 88, 1106-1112.	2.9	93
9	Characteristics and Outcomes of Patients With Cerebral Venous Sinus Thrombosis in SARS-CoV-2 Vaccine–Induced Immune Thrombotic Thrombocytopenia. JAMA Neurology, 2021, 78, 1314.	9.0	89
10	Regulatory T cells fail to suppress CD4 <sup>+ </sup> Tâ€bet <sup>+</sup> T cells in relapsing multiple sclerosis patients. Immunology, 2009, 127, 418-428.	4.4	78
11	Neurotrophic Factors and Clinical Recovery in Relapsing-Remitting Multiple Sclerosis. Scandinavian Journal of Immunology, 2005, 62, 176-182.	2.7	77
12	The effect of disease activity on leptin, leptin receptor and suppressor of cytokine signalling-3 expression in relapsing–remitting multiple sclerosis. Journal of Neuroimmunology, 2007, 192, 174-183.	2.3	74
13	Risk Factor and Etiology Analysis of Ischemic Stroke in Young Adult Patients. Journal of Stroke and Cerebrovascular Diseases, 2014, 23, e221-e227.	1.6	69
14	Neurotrophic factors in relapsing remitting and secondary progressive multiple sclerosis patients during interferon beta therapy. Clinical Immunology, 2006, 118, 77-82.	3.2	58
15	IL17 and IFNÎ <sup>3</sup> production by peripheral blood mononuclear cells from clinically isolated syndrome to secondary progressive multiple sclerosis. Cytokine, 2008, 44, 22-25.	3.2	53
16	Acute necrotizing encephalopathy during novel influenza A (H1N1) virus infection. Annals of Neurology, 2010, 68, 111-114.	5.3	51
17	Relapsing-remitting autoimmune agrypnia. Annals of Neurology, 2001, 50, 668-671.	5.3	44
18	Distinctive clinical and neuroimaging characteristics of longitudinally extensive transverse myelitis	3.6	44

associated with aquaporin-4 autoantibodies. Journal of Neurology, 2013, 260, 2396-2402.

#	Article	IF	CITATIONS
19	"Better explanations―in multiple sclerosis diagnostic workup. Neurology, 2019, 92, e2527-e2537.	1.1	44
20	CD8+Foxp3+ T cells in peripheral blood of relapsing-remitting multiple sclerosis patients. Human Immunology, 2010, 71, 437-441.	2.4	42
21	Effect of lockdown on the management of ischemic stroke: an Italian experience from a COVID hospital. Neurological Sciences, 2020, 41, 2309-2313.	1.9	39
22	Sleep and fatigue in multiple sclerosis: A questionnaire-based, cross-sectional, cohort study. Journal of the Neurological Sciences, 2017, 372, 387-392.	0.6	37
23	Movement disorders in multiple sclerosis: causal or coincidental association?. Multiple Sclerosis Journal, 2008, 14, 1284-1287.	3.0	35
24	Increased CD4+CD25+Foxp3+ T cells in peripheral blood of celiac disease patients: Correlation with dietary treatment. Human Immunology, 2009, 70, 430-435.	2.4	35
25	Motor cortex stimulation for ALS: A double blind placebo-controlled study. Neuroscience Letters, 2009, 464, 18-21.	2.1	33
26	Epstein-Barr virus antibodies in serum and cerebrospinal fluid from Multiple sclerosis, Chronic Inflammatory Demyelinating Polyradiculoneuropathy and Amyotrophic Lateral Sclerosis. Journal of Neuroimmunology, 2010, 225, 149-152.	2.3	33
27	Bilateral thalamic stroke transiently reduces arousals and NREM sleep instability. Journal of the Neurological Sciences, 2011, 300, 151-154.	0.6	33
28	pSTAT1, pSTAT3, and Tâ€bet as markers of disease activity in chronic inflammatory demyelinating polyradiculoneuropathy. Journal of the Peripheral Nervous System, 2009, 14, 107-117.	3.1	31
29	Leptin Enhances the Release of Cytokines by Peripheral Blood Mononuclear Cells from Relapsing Multiple Sclerosis Patients. Journal of Clinical Immunology, 2004, 24, 287-293.	3.8	30
30	CD4 <sup>+</sup> T-bet <sup>+</sup> , CD4 <sup>+</sup> pSTAT3 <sup>+</sup> and CD8 <sup>+</sup> T-bet <sup>+</sup> T cells accumulate in peripheral blood during NZB treatment. Multiple Sclerosis Journal, 2011, 17, 556-566.	3.0	30
31	An Italian Neurology Outpatient Clinic Facing SARS-CoV-2 Pandemic: Data From 2,167 Patients. Frontiers in Neurology, 2020, 11, 564.	2.4	30
32	Increased expression of T-bet in circulating B cells from a patient with multiple sclerosis and celiac disease. Human Immunology, 2008, 69, 837-839.	2.4	27
33	Circulating CD56dim NK cells expressing perforin are increased in progressive multiple sclerosis. Journal of Neuroimmunology, 2013, 265, 124-127.	2.3	27
34	Severe Disability in Patients with Relapsing-Remitting Multiple Sclerosis Is Associated with Profound Changes in the Regulation of Leptin Secretion. NeuroImmunoModulation, 2013, 20, 341-347.	1.8	26
35	Glucocorticoid treatment reduces T-bet and pSTAT1 expression in mononuclear cells from relapsing remitting multiple sclerosis patients. Clinical Immunology, 2007, 124, 284-293.	3.2	25
36	Tissue-Infiltrating Lymphocytes Analysis Reveals Large Modifications of the Duodenal "Immunological Niche―in Coeliac Disease After Gluten-Free Diet. Clinical and Translational Gastroenterology, 2012, 3, e28.	2.5	25

#	Article	IF	CITATIONS
37	Serum Levels of Anti-Myelin Antibodies in Relapsing-Remitting Multiple Sclerosis Patients during Different Phases of Disease Activity and Immunomodulatory Therapy. Disease Markers, 2005, 21, 49-55.	1.3	23
38	Light chain deposition in peripheral nerve as a cause of mononeuritis multiplex in Waldenström's macroglobulinaemia. Journal of the Neurological Sciences, 2010, 291, 89-91.	0.6	23
39	Clinical characteristics, course and prognosis of spinal multiple sclerosis. Spinal Cord, 2005, 43, 731-734.	1.9	22
40	The persistency of high levels of pSTAT3 expression in circulating CD4+ T cells from CIS patients favors the early conversion to clinically defined multiple sclerosis. Journal of Neuroimmunology, 2008, 205, 126-134.	2.3	22
41	T-bet and pSTAT-1 expression in PBMC from coeliac disease patients: new markers of disease activity. Clinical and Experimental Immunology, 2009, 158, 106-114.	2.6	22
42	T-bet, pSTAT1 and pSTAT3 expression in peripheral blood mononuclear cells during pregnancy correlates with post-partum activation of multiple sclerosis. Clinical Immunology, 2009, 131, 70-83.	3.2	21
43	Management of Cerebral Venous Thrombosis Due to Adenoviral <scp>COVID</scp> â€19 Vaccination. Annals of Neurology, 2022, 92, 562-573.	5.3	21
44	A human anti-neuronal autoantibody against GABAB receptor induces experimental autoimmune agrypnia. Experimental Neurology, 2007, 204, 808-818.	4.1	20
45	Multiple sclerosis attacks triggered by hyperprolactinemia. Journal of Neuro-Oncology, 2010, 98, 407-409.	2.9	20
46	Second-Line Therapy with Fingolimod for Relapsing-Remitting Multiple Sclerosis in Clinical Practice: The Effect of Previous Exposure to Natalizumab. European Neurology, 2015, 73, 57-65.	1.4	20
47	Delirium in acute stroke: A prospective, crossâ€sectional, cohort study. European Journal of Neurology, 2021, 28, 1590-1600.	3.3	19
48	Tourettism in Multiple Sclerosis: A case report. Journal of the Neurological Sciences, 2009, 287, 288-290.	0.6	18
49	Autonomic Dysfunction during Acute SARS-CoV-2 Infection: A Systematic Review. Journal of Clinical Medicine, 2022, 11, 3883.	2.4	18
50	Evidence of involvement of leptin and IL-6 peptides in the action of interferon-beta in secondary progressive multiple sclerosis. Peptides, 2005, 26, 2289-2293.	2.4	17
51	Thyroid autoimmunity and dysfunction in multiple sclerosis patients during long-term treatment with interferon beta or glatiramer acetate: an Italian multicenter study. Multiple Sclerosis Journal, 2014, 20, 1265-1268.	3.0	17
52	Predicting Factors of Functional Outcome in Patients with Acute Ischemic Stroke Admitted to Neuro-Intensive Care Unit—A Prospective Cohort Study. Brain Sciences, 2020, 10, 911.	2.3	16
53	Cerebral venous thrombosis due to vaccine-induced immune thrombotic thrombocytopenia after a second ChAdOx1 nCoV-19 dose. Blood, 2022, 139, 2720-2724.	1.4	16
54	Spontaneous recovery from anti-NMDAR encephalitis. Journal of Neurology, 2012, 259, 1964-1966.	3.6	14

#	Article	IF	CITATIONS
55	Instrumental Evaluation of COVID-19 Related Dysautonomia in Non-Critically-III Patients: An Observational, Cross-Sectional Study. Journal of Clinical Medicine, 2021, 10, 5861.	2.4	14
56	Glioblastoma in multiple sclerosis: a case report. Journal of Neuro-Oncology, 2009, 94, 141-144.	2.9	13
57	Type 1 immune response in progressive multiple sclerosis. Journal of Neuroimmunology, 2012, 249, 112-116.	2.3	13
58	Neurofibromatosis Type 1 Associated with Vertebrobasilar Dolichoectasia and Pontine Ischemic Stroke. Journal of Neuroimaging, 2015, 25, 505-506.	2.0	13
59	lschemic stroke: clinical pathway impact. International Journal of Health Care Quality Assurance, 2019, 32, 588-598.	0.9	13
60	Stroke and COVID19: Not only a large-vessel disease. Journal of Stroke and Cerebrovascular Diseases, 2020, 29, 105074.	1.6	13
61	Circulating CD8+CD56â^'perforin+ T cells are increased in multiple sclerosis patients. Journal of Neuroimmunology, 2011, 240-241, 137-141.	2.3	12
62	Autonomic dysfunction in non-critically ill COVID-19 patients during the acute phase of disease: an observational, cross-sectional study. Neurological Sciences, 2022, 43, 4635-4643.	1.9	12
63	Involvement of type I immune responses in swine-origin H1N1 influenza virus infection. Human Immunology, 2011, 72, 632-635.	2.4	11
64	Breastfeeding and Multiple Sclerosis. Archives of Neurology, 2009, 66, 1580.	4.5	10
65	Dysphagia and Obstructive Sleep Apnea in Acute, First-Ever, Ischemic Stroke. Journal of Stroke and Cerebrovascular Diseases, 2018, 27, 539-546.	1.6	10
66	Effect of the COVID-19 pandemic and the lockdown measures on the local stroke network. Neurological Sciences, 2021, 42, 1237-1245.	1.9	10
67	Posterior Circulation Endovascular Thrombectomy for Large Vessels Occlusion in Patients Presenting with NIHSS Score ≤0. Life, 2021, 11, 1423.	2.4	9
68	Stroke integrated care pathway during COVID-19 pandemic. Neurological Sciences, 2020, 41, 1673-1675.	1.9	8
69	Mechanical Thrombectomy for Acute Intracranial Carotid Occlusion with Patent Intracranial Arteries. Clinical Neuroradiology, 2021, 31, 21-29.	1.9	8
70	Oculogyric Crisis in a Midbrain Lesion. Archives of Neurology, 2011, 68, 390-1.	4.5	8
71	Prospective Observational Study of Safety of Early Treatment with Edoxaban in Patients with Ischemic Stroke and Atrial Fibrillation (SATES Study). Brain Sciences, 2021, 11, 30.	2.3	8
72	Brainstem and spinal cord involvement in a paraneoplastic syndrome associated with anti-Yo antibody and breast cancer. Journal of Neurology, 2011, 258, 921-922.	3.6	7

#	Article	IF	CITATIONS
73	Coeliac disease presenting with acute disseminated encephalomyelitis. European Journal of Neurology, 2006, 13, 202-203.	3.3	6
74	A Prospective Study on 132 Cases of Ocular Palsy. European Neurology, 2013, 70, 10-15.	1.4	6
75	COVID-19 and stroke: from the cases to the causes. Reviews in the Neurosciences, 2021, 32, 659-669.	2.9	6
76	In vivo Effects of Mitoxantrone on the Production of Pro- and Anti-Inflammatory Cytokines by Peripheral Blood Mononuclear Cells of Secondary Progressive Multiple Sclerosis Patients. NeuroImmunoModulation, 2006, 13, 76-81.	1.8	5
77	Thalamic Amnesia Mimicking Transient Global Amnesia. Neurologist, 2015, 19, 149-152.	0.7	5
78	Super-Refractory Status Epilepticus. Clinical EEG and Neuroscience, 2015, 46, 335-339.	1.7	5
79	Post-Encephalitic Parkinsonism and Sleep Disorder Responsive to Immunological Treatment. Clinical EEG and Neuroscience, 2016, 47, 324-329.	1.7	5
80	Low reliability of anti-KIR4.183–120 peptide auto-antibodies in multiple sclerosis patients. Multiple Sclerosis Journal, 2018, 24, 910-918.	3.0	5
81	Complement-mediated cytotoxicity of antibodies to the GABAB receptor. Lancet Neurology, The, 2010, 9, 343.	10.2	4
82	Vertebral Artery Dissection Presenting With Isolated Occipital Headache. Headache, 2010, 50, 1378-1380.	3.9	4
83	Pneumonia's link with the head and heart. Lancet, The, 2010, 376, 388.	13.7	4
84	From High- to Low-Frequency Administered Interferon-Beta for Multiple Sclerosis: A Multicenter Study. European Neurology, 2014, 71, 233-241.	1.4	4
85	Neurological involvement during legionellosis, look beyond the lung. Journal of Neurology, 2012, 259, 2243-2245.	3.6	3
86	A cross-sectional, multicentre study of the therapeutic management of multiple sclerosis relapses in Italy. Neurological Sciences, 2013, 34, 197-203.	1.9	3
87	Sleep Modifications in Acute Transient Global Amnesia. Journal of Clinical Sleep Medicine, 2013, 09, 921-927.	2.6	3
88	Sleep disorder associated with antibodies to IgLON5: parasomnia or agrypnia?. Lancet Neurology, The, 2014, 13, 864.	10.2	3
89	Ventral Longitudinal Intraspinal Fluid Collection Presenting as Upper Limb Amyotrophy. European Neurology, 2018, 80, 126-127.	1.4	3
90	Demyelinating encephalomyeloradiculitis with Balò-like lesions. Journal of Neurology, 2010, 257, 1566-1567.	3.6	2

#	Article	IF	CITATIONS
91	Spontaneous sternocleidomastoid muscle hematoma following thrombolysis for acute ischemic stroke. Journal of the Neurological Sciences, 2014, 341, 189-190.	0.6	2
92	Distinct lymphocytes subsets in IgM-related neuropathy: clinical-immunological correlations. Neurological Sciences, 2015, 36, 303-308.	1.9	2
93	A Case of Hemiabdominal Myoclonus. Clinical EEG and Neuroscience, 2015, 46, 331-334.	1.7	2
94	Mechanical thrombectomy in patients with stroke due to large vessel occlusion in the anterior circulation and low scale score. Journal of Integrative Neuroscience, 2021, 20, 645.	1.7	2
95	Role of Favorable Perfusion Imaging in Predicting the Outcome of Patients with Acute Ischemic Stroke due to Large Vessel Occlusion Undergoing Effective Thrombectomy: A Single-Center Study. Cerebrovascular Diseases Extra, 2021, 11, 1-8.	1.5	2
96	The Stolen Memory: A Case of Transient Global Amnesia. Biological Psychiatry, 2010, 67, e31-e32.	1.3	1
97	Nine syndrome. Acta Neurologica Belgica, 2019, 119, 475-476.	1.1	1
98	A man with sarcoidosis and slurred speech. European Journal of Neurology, 2020, 27, e7-e8.	3.3	1
99	Cerebral edema in acute stroke: Effect of thrombolytic treatment. Journal of the Neurological Sciences, 2022, 436, 120206.	0.6	1
100	Focal Hyperhidrosis in Tumefactive Multiple Sclerosis. Archives of Neurology, 2010, 67, 1407-8.	4.5	0
101	Response to the letter to the Editor for the manuscript "Sleep and Fatigue in Multiple Sclerosis: A questionnaire-based, cross-sectional, cohort study―by Tomoyuki Kawada. Journal of the Neurological Sciences, 2017, 373, 142.	0.6	0
102	Thrombus in Transit. Neurologist, 2017, 22, 21-23.	0.7	0
103	Acute upward gaze palsy: Not always Parinaud syndrome. European Journal of Ophthalmology, 2020, 30, NP5-NP6.	1.3	0